70.0 B

Melanotan II

Also known as: MTII, MT-2

Strong Clinical Evidence Category 2 Restricted
Research Evidence 90.0/100
Safety Profile 50.0/100

38 Clinical Trials

Unknown: 2 PHASE4: 7 PHASE3: 3 PHASE2, PHASE3: 1 PHASE2: 6 PHASE1, PHASE2: 3 PHASE1: 3 NA: 12 EARLY_PHASE1: 1

Showing 5 of 38 trials.

20 Research Papers

Showing 5 of 20 papers by citation count.

FDA Data

Not FDA-Approved

Melanotan II has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.

Frequently Asked Questions

Is Melanotan II FDA approved?
No, Melanotan II is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has Melanotan II been studied in?
Melanotan II has been studied in 38 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Melanotan II?
Melanotan II has a CheckPeptides trust score of 70.0/100 (grade: B). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026

Quick Facts

Classification
Melanocortin receptor agonist
Molecular Weight
1024.2 Da
Regulatory Status
N/A

Score Breakdown

Research Evidence 90.0/100
Safety Profile 50.0/100

Evidence Summary

Clinical Trials
38
Research Papers
20
Trust Score
70.0/100
Grade
B

Compare Peptides

See how Melanotan II stacks up against similar peptides.

View Comparisons
← Browse all peptides